CSS
HUMA icon

Cubist Systematic Strategies’s Humacyte HUMA Stock Holding History

Cubist Systematic Strategies’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,816
Closed -$46K – 4126
2022
Q4 		$46K Buy
+21,816
New +$66.2K ﹤0.01% 3912
2022
Q3 		– Sell
-19,500
Closed -$63K – 4552
2022
Q2 		$63K Sell
19,500
-28,775
-60% -$160K ﹤0.01% 4058
2022
Q1 		$341K Sell
48,275
-45,510
-49% -$265K ﹤0.01% 2768
2021
Q4 		$680K Buy
+93,785
New +$928K 0.01% 2212

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IW
Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cubist Systematic Strategies's HUMA Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Humacyte (HUMA) in Q1 2023, closing a stake of 21,816 shares — an estimated $46K sold.

Cubist Systematic Strategies first reported a position in HUMA in Q4 2021 and held it in 4 quarters. The position peaked at $680K in Q4 2021. 69 funds tracked by Wall St. Rank hold HUMA as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining Humacyte position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 21,816 Humacyte shares in Q1 2023, an estimated $46K.
  • Cubist Systematic Strategies first reported a position in Humacyte in Q4 2021 and held it in 4 quarters.
  • Cubist Systematic Strategies's Humacyte position peaked at $680K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Humacyte as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.